CD44 and cancer: Taking into consideration the record of clinical trials based on CD44 targeting, which revealed lack of efficiency in the clinical setting, it is needed to highlight that the glycoprofile of cancer-specific CD44v isoforms could be an answer for future studies and likely the success of such CD44-targeting mAbs.